- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03889613
Pillcam Crohn's Capsule for Monitoring of Panenteric Mucosal Healing in Crohn's Disease Patients With Vedolizumab
Pillcam Crohn's Capsule for Monitoring of Pan Enteric Mucosal Healing in Crohn's Disease Patients Treated With Vedolizumab
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mucosal healing has been widely accepted as the ultimate therapeutic goal in treatment of IBD patients and is associated with improved short and long-term outcomes in both ulcerative colitis and Crohn's disease (CD). However, the vast majority of the available clinical data pertains to colonic mucosal healing. In CD, the small bowel is involved in at least 75% of the patients, frequently in locations that are not accessible to ileocolonoscopy Active small bowel disease can be detected in at least 50% of CD patients in clinical remission[3]. Moreover, colonic and small bowel mucosal healing do not parallel each other, and it is quite common to detect inflammation in one segment while the other demonstrates endoscopically active disease.
Small bowel capsule endoscopy (SBCE) is the prime modality for evaluation of the entire small bowel[5]. It provides a safe and accurate way to screen and evaluate the entire small bowel, using a clinically validated endoscopic score such as the Lewis score (LS). Several studies evaluated the use of SBCE in monitoring mucosal healing in Crohn's disease, in both active and quiescent disease. The safety profile of SBCE in CD is excellent, especially after verification of small bowel patency using a patency capsule (PC).
To date, prospective data pertaining to the efficacy of biologics in induction of small bowel mucosal healing is very limited. The only prospective study to date was relatively small (36 patients) and demonstrated a significant improvement in mucosal inflammation and achievement of mucosal healing in patients that received Adalimumab and were evaluated with SBCE at week 0, 12 and 52 The rate of mucosal healing increased significantly from week 12 to 54.. No such data exists for other biologics. Recently, a combined pan-enteric capsule (PillCam Crohn's capsule) was developed by Medtronic. The capsule is based on an existing PillCam Colon 2 with a modified reading software. This capsule enables evaluation of mucosal inflammation and healing in the entire digestive tract in a single safe and non-invasive procedure. The new software of Rapid 9 includes a new method of describing the inflammatory burden on each of the 3 tertiles of the small bowel and two of the colon as well as the "old" Lewis score. In a feasibility 5 center prospective trial the capsule exited the colon while photographing in 83% of patients and reached the recto-sigma in 95%.
Intestinal ultrasound (IUS) is an accurate, safe and cheap modality for bedside evaluation of the small bowel. It was evaluated for both diagnosis and monitoring of intestinal inflammation in CD, and can be also utilized to assess the response to treatment. Recently, a quantitative score (Limberg index (LI)) for quantification of small bowel inflammation on IUS was validated.
The aim of our study is to assess the utility of the Pillcam Crohn's capsule in assessment of panenteric mucosal healing in CD patients treated with vedolizumab Study interventions
Visit 1 (before vedolizumab is started):
- Clinical activity
- Patients will perform patency capsule (PC) and give fecal sample for FC and microbiome.
- If PC is safely excreted within 30 hours and FC > 100 mg/kg, the patient will undergo SBC and will be enrolled if LS ≥ 220 or CDEIS>5.
- Blood will be drawn for measurement of CRP levels and complete blood count (CBC).
- IUS will be performed. Second visit and third visit(week 14 and 52): will include clinical evaluation, CBC, CRP, FCP, microbiome, SBC and IUS.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ramat Gan, Israel, 52621
- Sheba Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Crohn's disease
- planned to initiate VDZ treatment as recommended by the treating physician
- age- 18-70
- active small bowel inflammation on SBC (LS ≥ 220 or SES-CD>5 or active inflammation on the Pillcam Crohn's capsule score and FC>100 mg/kg)
Exclusion criteria:
- History of small bowel radiation
- History of previous capsule retention
- Previous treatment with vedolizumab
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: all patients
All enrolled patients- prospective observation (all patients are followed using videocapsule)
|
prospective follow-up with videocapsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Panenteric mucosal healing
Time Frame: 52 weeks
|
Percentage of patients achieving pan enteric mucosal healing at week 52 post VDZ initiation as assessed by the Pillcam Crohn's capsule
|
52 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHEBA-18-4710-UK-CTIL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Sheba Medical CenterActive, not recruiting
-
NHS Greater Glasgow and ClydeUnknown
Clinical Trials on prospective follow-up with videocapsule
-
Hospices Civils de LyonCompletedDiabetes in Cystic Fibrosis PatientsFrance
-
Assiut UniversityRecruitingMullerian Duct AnomaliesEgypt
-
St. Justine's HospitalCanadian Institutes of Health Research (CIHR)RecruitingPediatric Acute Respiratory Distress SyndromeCanada
-
University Hospital of FerraraRecruitingAcute Coronary SyndromesItaly
-
Inova Health Care ServicesRecruiting
-
Institute of Psychiatry and Neurology, WarsawUnknown
-
Pontificia Universidad Catolica de ChileUniversity of Technology, SydneyCompletedCardiovascular Diseases | Hypertension | Type 2 Diabetes Mellitus | Dyslipidemias | Medication Adherence | Drug UseChile
-
Rabin Medical CenterUnknown
-
Insel Gruppe AG, University Hospital BernUniversity of BernActive, not recruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting